Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02842138Phase 1Unknown

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

Role: collaborator

NCT03208556Phase 1Unknown

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Role: collaborator

NCT02937844Phase 1Unknown

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

Role: collaborator

NCT02930967Phase 1Unknown

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Role: collaborator

NCT02930993Phase 1Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Role: collaborator

NCT02844062Phase 1Unknown

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Role: collaborator

All 6 trials loaded